Your session is about to expire
← Back to Search
Olaparib + Pembrolizumab for Melanoma
Study Summary
This trial is testing a combination of drugs to treat patients with advanced melanoma that has progressed despite other treatments. Olaparib may stop the growth of tumor cells, and pembrolizumab may help the immune system attack the tumor. The trial will assess the safety and effectiveness of the combination.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had lung inflammation from specific cancer treatment that needed steroids.I have had an organ, bone marrow, or cord blood transplant for cancer.My cancer has a specific genetic mutation.My brain metastases are stable, and I haven't needed steroids for 14 days.I have had only one chemotherapy treatment but may have had multiple immunotherapy or targeted therapy treatments.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I have an autoimmune disease treated with medication in the last 2 years.My melanoma cannot be removed by surgery and is in stage III or IV.Your disease can be measured using a specific standard called RECIST 1.1.I am fully active or restricted in physically strenuous activity but can do light work.I have recovered from side effects of previous treatments to my normal or mild condition.My cancer did not respond or stopped responding to PD-1 inhibitors, and if it has the BRAF mutation, it also did not respond to BRAF inhibitors or I couldn't tolerate the treatment.I have been treated with a PARP inhibitor before.I had radiotherapy less than 2 weeks ago, except for short-term palliative care.I have another cancer that is getting worse or was treated in the last 2 years.
- Group 1: Olaparib + Pembrolizumab
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Olaparib been trialed in other medical experiments?
"As of this moment, 1114 clinical trials for Olaparib are in operation. Of these studies, 143 have progressed to the third stage of development. Though the majority is based in Houston, Texas there are 42747 sites where research about this medication is being conducted."
What indications is Olaparib typically recommended for?
"Olaparib is primarily prescribed to treat unresectable melanoma, but has been known to be effective in the management of microsatellite instability high and cases with a heightened risk of relapse."
Is this a fresh endeavor in medical trials?
"Olaparib has been the subject of clinical research since 2005 when AstraZeneca completed their first trial involving 98 participants. This study led to Olaparib's Phase 1 drug approval and today there are 1114 active studies in 3058 cities from 66 countries around the world."
What is the upper limit of participants for this research endeavor?
"Affirmative. Clinicaltrials.gov suggests that this medical trial is actively enrolling participants; it was first made available on March 3rd 2021 and the most recent update occurred April 30th 2021. The research requires 41 individuals from one location to take part in the study."
Is enrolment in this experiment currently available to participants?
"This clinical trial, first posted on March 3rd 2021, is actively recruiting study participants. The data hosted by clinicaltrials.gov was last updated April 30th of this year."
How can the risk of adverse effects be minimized when administering Olaparib?
"The safety of Olaparib is rated as a 2 on our scale, based off the fact that Phase 2 trials have only demonstrated preliminary evidence regarding its safety but no proof of efficacy."
Share this study with friends
Copy Link
Messenger